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Methods: Rats were given an intra-amygdala injection of kainic acid to induce epilepsy. Groups of rats
were treated with rhEPO or CEPO before induction of epilepsy, whereas additional rats were given a
caudal vein injection of AG490, a selective inhibitor of Janus kinase 2 (JAK2). At different time points after
seizure onset, electroencephalogram changes were recorded, and myocardium samples were taken for the
detection of myocardial cell apoptosis and expression of JAK2, signal transducer and activator of
transcription 5 (STAT5), caspase-3, and bcl-xl mRNAs and proteins.
Results: Induction of epilepsy signiﬁcantly enhanced myocardial cell apoptosis and upregulated the
expression of caspase-3 and bcl-xl proteins and JAK2 and STAT5a at both the mRNA and protein levels.
Pretreatment with either rhEPO or CEPO reduced the number of apoptotic cells, upregulated bcl-xl
expression, and downregulated caspase-3 expression in the myocardium of epileptic rats. Both myocardial
JAK2 and STAT5a mRNAs, as well as phosphorylated species of JAK2 and STAT5a, were upregulated in
epileptic rats in response to rhEPO—but not to CEPO—pretreatment. AG490 treatment increased apoptosis,
upregulated caspase-3 protein expression, and downregulated bcl-xl protein expression in the myocar-
dium of epileptic rats.
Conclusions: These results indicate that myocardial cell apoptosis may contribute to myocardial injury in
epilepsy. EPO protects myocardial cells from apoptosis via the JAK2/STAT5 pathway in rats with
experimental epilepsy, whereas CEPO exerts antiapoptotic activity perhaps via a pathway independent
of JAK2/STAT5 signaling.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Epilepsy is a common chronic neurologic disorder that affects
approximately 50 million people worldwide.1 Although the major-
ity of cases can be controlled with medication, some 20% to 30% of
patients do not respond to medical treatment and develop intract-
able epilepsy.2 Repeated epileptic seizures often disturb neuro-
humoral regulation and thereby induce dysfunction of organs
other than the nervous tissue.3,4 Patients with intractable epilepsy
may show ECG abnormalities such as ST-segment depression and
T-wave inversion, transient left ventricular dysfunction, and the
release of cardiac enzymes into plasma.5,6 These manifestations
are similar to the symptoms of stress-induced cardiomyopathy.5Inc. This is an open access article u
epartment of Geriatrics, First
.
).
.Additionally, epilepsy is associated with the risk of cardiac ischemia
and myocardial infarction.6,7 However, the mechanism(s) underlying
epilepsy-induced myocardial injury remains unclear.
Erythropoietin (EPO) is a glycoprotein produced by kidneys
that promotes the formation of red blood cells in bone marrow.
Besides acting as an erythropoiesis-stimulating hormone, EPO has
a much broader range of action. Of relevance to the present study,
several lines of evidence have indicated that EPO can exert
antiepileptic effects and prevent epilepsy-associated impair-
ments.8,9 Furthermore, numerous studies demonstrate that EPO
is cardioprotective.10–14 Interestingly, both the neuroprotective
and cardioprotective actions of EPO are dependent on its anti-
apoptotic activity (ie, antiapoptotic gene upregulation and apop-
totic gene downregulation) and the activation of the Janus-
activated kinase (JAK)/signal transducer and activator of tran-
scription (STAT) pathway.12,15,16 We therefore hypothesized that
EPO may protect myocardial cells from apoptosis via the JAK2/
STAT5 pathway in epilepsy.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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whether apoptosis plays a role in the pathogenesis of myocardial
injury in a rat model of epilepsy. Moreover, we examined whether
EPO exerts protective effects against myocardial injury in epilepsy
and whether the JAK2/STAT5 pathway is involved in this process.
Our results indicate that recombinant human EPO protects myo-
cardial cells from apoptosis via the JAK2/STAT5 pathway in kainic
acid (KA)-evoked epilepsy.Materials and Methods
Main reagents and equipment
Reagents and equipment used were stereotaxic apparatus (Seta-
gaya-ku, Tokyo, Japan); dental drills (Saeshin, Daegu, South Korea);
micropipettes (Ningbo, Jiangsu, China); EPO (lot No. 20081047;
ClonBiotech, Shanghai, China); KA (Sigma, Shanghai, China); TUNEL
Assay Kit (Roche, Basal, Switzerland); anti-bcl-xl antibody (sc-8392;
Santa Cruz Biotechnology, Texas, USA); anticaspase-3 antibody (sc-
7148; Santa Cruz Biotechnology); in situ hybridization kits for
detection of JAK2, STAT5a, and STAT5b mRNAs (Haoyang Biological,
Tianjin, China); and Western blot assay kits for detection of p-JAK2
and p-STAT5 proteins (Cell Signaling Technology, Boston, USA).
Carbamylation of EPO
EPO was carbamylated by incubation at 371C with 2000 mM
cyanate for 24 hours. These carbamylated EPOs (CEPOs) were
followed by extensive dialysis against total 12 L phosphate-
buffered saline at pH 7.4 and a temperature of 41C to remove excess
cyanate. After dialysis, EPO was used for the reaction with trinitro-
benzenesulfonic acid. The extent of carbamylation was monitored by
following the loss of free amino groups using trinitrobenzenesul-
fonic acid. Fifty microliters of 0.1% trinitrobenzenesulfonic acid was
added to 1 mL EPO (500 U/mL in normal saline) and 1 mL 4% sodium
hydrogen carbonate (pH 8.4) and this was incubated for 1 hour at
371C. Absorbance was then measured at 340 nm against a sample
blank, and the trinitrobenzenesulfonic acid reactivity was expressed
as a percentage of the absorbance obtained for the non-CEPO.
Animal groups
One hundred eighty-six healthy male Wistar rats, weighing 240
to 260 g, were obtained from the Laboratory Animal Center of Jilin
University. Six rats receiving no treatment were used as normal
controls. The remaining rats were equally divided into 6 groups:
phosphate buffered saline (PBS) group, epilepsy group, EPO group,
CEPO group, AG490 (a selective inhibitor of JAK2) group, and
ethanol group. These 6 groups were further divided into 5 sub-
groups for testing at 0, 2, 6, 12, and 24 hours after seizure onset.
This gave a total of 6 rats per time point studied. The PBS group
was given an intra-amygdala injection of 1 μL PBS, whereas all
other groups received an equal volume of KA. EPO (250 IU) and
CEPO (250 IU) were administered to rats in the EPO group and
CEPO group via the caudal vein 24 hours before the induction of
epilepsy, respectively, whereas equal volumes of normal saline
were given to rats in the PBS and epilepsy groups. The AG490 and
ethanol groups were injected with AG490 (0.25 mg, dissolved in
ethanol) and ethanol, respectively, via the caudal vein at the time
of induction of epilepsy.
Induction of epilepsy
All surgical procedures were performed according to the Guide
for the Care and Use of Laboratory Animals. Rats were anesthetizedwith 10% chlorpromazine (3.3 mg/kg IP) and ﬁxed in a stereotaxic
apparatus with ear bars. A rhomboid skin incision was made along
the midline of the skull to expose the skull, bregma, and lambda. A
dental drill was then used to make a hole in the skull to expose the
dura mater. One microliter of KA (1 mg/mL in PBS) was injected at a
speed of 1 μL/min into the right amygdala (2.5 mm posterior to the
bregma, 5.0 mm lateral to midline, 8.0 mm below the skull surface).
Before KA injection, a bipolar electrode was positioned into the
hippocampal CA3 region (3.0 mm posterior to the bregma, 3.0 mm
lateral to midline, and 4.0 mm below the skull surface) in some rats.
The needle was slowly withdrawn 5 minutes after injection to
ensure complete absorption of KA. At the completion of injection,
the skin incision was sutured. The behavior of rats was evaluated
according to the Racine scale: stage 0, normal behavior; stage 1, wet
dog shakes and facial clonus, including eye blinking, whisker
twitching, and rhythmic chewing; stage 2, rhythmic nodding; stage
3, forelimb clonus; stage 4, bilateral forelimb clonus with rearing;
and stage 5, rearing, falling, loss of balance, and twitching.17 Epilepsy
was considered successfully induced when rats developed manifes-
tations of stage 4 or above, and spike waves and sharp waves were
monitored on a hippocampal EEG.
Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay
At 0, 2, 6, 12, and 24 hours after seizure onset, rats were
anesthetized with 10% chlorpromazine and perfused intracardially
with normal saline, followed by 10% buffered formalin. Myocardial
tissue samples were taken, ﬁxed in 10% neutral buffered formalin,
embedded in parafﬁn, and sectioned. After routine deparafﬁnization
and hydration, sections were used to detect the apoptosis of
myocardial cells with a TUNEL assay kit according to the manufac-
turer’s instructions. The nuclei of positive cells were stained brown.
Quantitative analysis was performed on 5 randomly selected ﬁelds
using Image-Pro Plus 6.0 software (Media Cybernetics, USA).
Immunohistochemistry
Myocardial tissue sections were prepared as described above
and stained by immunohistochemistry using the streptavidin-
peroxidase method to detect the expression of bcl-xl and
caspase-3 proteins. Positive staining was assessed by the degree
of brown color developed. The integrated optical density of
positive staining was measured using Image-Pro Plus 6.0 software.
In situ hybridization
In situ hybridization was performed to detect JAK2, STAT5a, and
STAT5b mRNAs using commercially available kits according to the
manufacturer’s instructions. The sequences of primers used for
probe synthesis were as follows: JAK2: (i) 5'-GCCGC CACTG AGCAA
AAAGG TAAGA CAT-3', (ii) 5'-CACTT TCCTT ATGTT TCCCT CTTGA
CCAC-3', (iii) 5'-TCGCT CAACG GCAAA GGTCA GGAAG TAT-3';
STAT5a: (i) 5'-GATGG TCTGC TGCTT CCTCA ACAAC TG-3', (ii) 5'-
ATGAA CAATG ACGAC CACAG GGAGG GACA-3', (iii) 5'-GGCTT
CAGAT TCCAC AGGTT TCGGT C-3'; and STAT5b: (i) 5'-CACTG GGATA
AATAA TGTCG CACCT CG-3', (ii) 5'-CCCCA TCGTT CCAGT GAGGC
TTGAG A-3'. The integrated optical density of positive staining was
measured using Image-Pro Plus 6.0 software.
Western blot
Myocardial cells were isolated from the rat myocardium and
lysed in radioimmunoprecipitation assay buffer. After centrifuga-
tion of lysates (12,000 rpm for 15 minutes at 41C) the super-
natants were quantiﬁed by the bicinchoninic acid method.
1mv
1mv
Figure 1. Spectral characteristics of EEG in (A) normal Wistar rats and (B) rats with
kainic acid-induced epilepsy. Normal brain waves have a frequency of 5 to 10 Hz
and an amplitude below 700 μV, whereas multiple forms of abnormal waveforms
are observed following induction of epilepsy.
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resolved on 15% sodium dodecyl sulfate-polyacrylamide gels
and transferred to polyvinylidene ﬂuoride membranes. The blots
were blocked for 60 minutes with 5% skimmed milk in PBS þ
0.1% Tween-20 at 371C and then incubated with rabbit anti-
p-JAK2 polyclonal antibody (1:1000) or rabbit anti-p-STAT5
polyclonal antibody (1:1000) overnight at 41C. Sections were
washed 3 times with PBS þ 0.1% Tween-20, incubated for 1 hour
at room temperature with horseradish peroxidase-labeled goat
antirabbit immunoglobulin G (1:5000), and then washed again as
above. Immunoblotted proteins were subsequently detected
using enhanced chemiluminescence. Blots were quantiﬁed using
Image-Pro Plus 6.0. Glyceraldehyde 3-phosphate dehydrogenase
was used to normalize equal protein loading.
Statistical analysis
Statistical analysis was performed using SPSS 11.5 software
(IBM-SPSS Inc, Armonk, New York). All data are expressed as mean
(SD). The difference between the means of 2 groups was compared
using the t test. The apoptosis rates, caspase-3 level, bcl-xl,
JAK2, and STAT5 were compared among groups by 1-way ANOVA
followed by the Student-Newman-Keuls test for multiple
comparisons. Two-sided values of P o 0.05 were considered to
be statistically signiﬁcant.Results
Hippocampal EEG spectral changes
In normal rats, brainwaves have a frequency of 5 to 10 Hz and
an amplitude below 700 μV (Figure 1A). After induction ofFigure 2. Epileptic rats showing symptoms of (A) Racine scale stage 4, bilateral forelimb
twitching.epilepsy with KA, multiple forms of epileptic discharges were
noted. Typical waveforms observed in epileptic rats included
monophasic, biphasic, and polyphasic spike waves, spike-slow
waves, paroxysmal rhythmic waves, and postseizure inhibition
(Figure 1B).
Behavior changes
With respect to strength, the motor seizures were rated on a
5-point scale, where 1¼mouth and facial movements, 2¼head
nodding, 3¼forelimb clonus, 4¼rearing, and 5¼rearing and fall-
ing. There is some variation in this progression, but most epileptic
rats develop motor seizures (Figure 2)
EPO and CEPO protect myocardial cells
TUNEL assays were performed to examine whether KA injec-
tion induced myocardial cell apoptosis and if EPO and CEPO exert
an antiapoptotic effect. As shown in Figure 3 and Table I, apoptotic
myocardial cells were only occasionally observed in normal control
rats. No signiﬁcant difference was noted in the extent of apoptosis
between the normal control and PBS groups (P 4 0.05). In the
epilepsy group, the number of apoptotic myocardial cells began to
increase rapidly 2 hours after the onset of seizures. Apoptosis
increased with time, peaking at 24 hours; at 24 hours apoptosis
was signiﬁcantly greater in the epilepsy group compared with the
PBS group (P o 0.01). Pretreatment with either EPO or CEPO
reduced the number of apoptotic myocardial cells in epileptic rats.
At 24 hours the extent of apoptosis was signiﬁcantly lower (P o
0.01) in both the EPO (15.127% [3.427%]) and CEPO (14.580%
[3.104%]) groups compared with the untreated epilepsy group
(19.648% [2.191%]). However, there was no signiﬁcant difference
between the EPO- and CEPO-treated groups (P 4 0.05). AG490
treatment resulted in a time-dependent increase in the number of
apoptotic myocardial cells in epileptic rats. The extent of apoptosis
at 24 hours was signiﬁcantly higher in the AG490 group compared
with the ethanol control group (P o 0.01). Additionally, the
apoptosis rates at 2, 6, 12, and 24 hours were signiﬁcantly higher
in the AG490 group than in either the EPO- or CEPO-treated group
(all P values o 0.01).
EPO and CEPO inhibit the expression of caspase-3
Immunohistochemistry was performed to examine whether
myocardial caspase-3 protein expression is altered following
induction of epilepsy and whether EPO or CEPO treatment
reversed any effect. As shown in Figure 4 and Table II, caspase-3
protein was expressed at low levels in the myocardium of normal
rats. No signiﬁcant difference was noted in the expression inten-
sity of caspase-3 protein between the normal control group andclonus with rearing and (B) Racine scale stage 5, rearing, falling, loss of balance, and
50 µm 50 µm
50 µm
50 µm
50 µm50 µm
Figure 3. Recombinant human erythropoietin (rhEPO) and carbamylated erythropoietin (CEPO) protects myocardial cells from apoptosis in rats with KA-induced epilepsy.
Apoptosis was measured in control (ie, phosphate buffered saline) and epileptic rats as well as epileptic rats treated with rhEPO, CEPO, ethanol, or AG490 by terminal
deoxynucleotidyl transferase dUTP nick end labeling assay at 0, 2, 6, 12, and 24 hours after the appearance of seizures. The ﬁgures show representative images (400 ; 24
hours after onset of seizure) of terminal deoxynucleotidyl transferase dUTP nick end labeling staining for apoptotic cells in the myocardium of (A) control and (B) epileptic
rats, as well as epileptic rats treated with (C) ethanol, (D) rhEPO, (E) CEPO, or (F) AG490. The nuclei of positive cells were stained brown (shown by arrows).
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caspase-3 protein in the myocardium began to be upregulated rapidly
2 hours after the onset of seizures. The expression intensity of caspase-
3 protein increased with time, peaking at 24 hours. The expression
intensity of caspase-3 protein at 24 hours was signiﬁcantly higher in
the epilepsy group than in the PBS group (P o 0.01). Pretreatment
with either EPO or CEPO reduced the expression of caspase-3
protein in epileptic rats, and the expression intensity of caspase-3
protein decreased with time, reaching the lowest level at the
24-hour time point. The expression intensity of caspase-3 proteinTable I
Apoptotic rate (%) in different time points and groups.
Time (h) Control Phosphate buffered saline Epilepsy Eryth
Mean (SD)
0 1.84 (0.86) 1.92 (1.05) 1.92 (0.98) 1.96
2 – 2.06 (0.86) 5.04 (1.80)*,║ 3.82
6 – 2.15 (0.93) 10.22 (2.27)*,║ 8.06
12 – 2.01 (0.95) 16.03 (1.91)*,║ 13.08
24 – 2.03 (0.87) 19.65 (2.19)*,║ 15.13
n Compared with phosphate buffered saline group, P o 0.01.
† Compared with epilepsy group, P o 0.01.
‡ Compared with epilepsy group, P o 0.05.
§ Compared with AG490 group, P o 0.01.
║ Compared with epilepsy 0 h group, P o 0.01.at 24 hours was signiﬁcantly lower in the EPO and CEPO groups
than in the epilepsy group (32,895.12 [5685.755] and 32,627.12
[5144.080] vs 43,922.68 [6459.093]; both P values o 0.01).
However, there was no signiﬁcant difference in the expression
intensity of caspase-3 protein between the EPO and CEPO groups
(P 4 0.05). AG490 treatment enhanced the expression of caspase-
3 protein in epileptic rats, and the expression intensity of caspase-
3 protein increased with time, peaking at 24 hours. The expression
intensity of caspase-3 protein at 24 hours was signiﬁcantly higher
in the AG490 group than in the ethanol-treated group (P o 0.01).ropoietin Carbamylated erythropoietin Ethanol AG490
(0.96) 2.02 (0.93) 1.83 (0.73) 2.00 (1.02)
(1.84)§ 4.04 (1.67)§ 4.98 (1.74)* 7.91 (1.73)
(1.79)§ 7.96 (1.84)§ 10.15 (1.83)* 13.14 (2.62)
(2.07)‡,§ 12.90 (2.06)†,§ 15.15 (2.02)* 19.74 (2.05)
(3.43)†,§ 14.58 (3.10)†,§ 19.91 (2.14)* 25.04 (2.12)
50 µm 50 µm
50 µm50 µm
50 µm 50 µm
Figure 4. Recombinant human erythropoietin (rhEPO) and carbamylated erythropoietin (CEPO) downregulate the expression of caspase-3 protein in the myocardium of rats
with kainic acid-induced epilepsy. Using immunohistochemistry the expression of caspase-3 protein in the myocardiumwas determined at 0, 2, 6, 12, and 24 hours after the
onset of seizures. The ﬁgures show representative images (400 ; 24 hours after onset of seizure) of caspase-3 expression in the myocardium of (A) control and (B) epileptic
rats as well as epileptic rats treated with (C) ethanol, (D) rhEPO, (E) CEPO, or (F) AG490. The cytoplasm of positive cells is stained brown (shown by arrows).
B.-X. Ma et al. / Current Therapeutic Research 77 (2015) 90–9894Additionally, the expression intensity of caspase-3 protein at 24
hours was signiﬁcantly higher in the AG490 group than in the EPO
and CEPO groups (both P values o 0.01).
EPO and CEPO enhance the expression of bcl-xl
To examine whether bcl-xl protein expression in the myocar-
dium is altered and whether EPO and CEPO affect such alteration
in epileptic rats, immunohistochemistry was performed. As shown
in Figure 5, bcl-xl protein was expressed at comparatively low
levels in the myocardium of normal rats. No signiﬁcant differenceTable II
Integrated optical density of caspase3 protein expression in different time points and g
Time (h) Control Phosphate buffered saline Epilepsy Erythrop
Mean (SD)
0 8368 (1470) 8358 (1034) 8197 (1306) 8254 (
2 – 8288 (992) 14,483 (2877)* 13,662 (
6 – 8199 (992) 19,247 (3051)* 17,909 (
12 – 8380 (871) 29,481 (4705)* 25,744 (
24 – 8286 (999) 43,923 (6459)* 32,895 (
n Compared with PBS group, P o 0.01.
† Compared with epilepsy group, P o 0.01.
‡ Compared with AG490 group, P o 0.01.
§ Compared with ethanol group, P o 0.01.was noted in the expression intensity of bcl-xl protein between the
normal control group and PBS group (P 4 0.05). In the epilepsy
group, the expression of bcl-xl protein in the myocardium began to
be upregulated rapidly 2 hours after the onset of seizures. The
expression intensity of bcl-xl protein increased with time, peaking
at 24 hours. The expression intensity of bcl-xl protein at 24 hours
was signiﬁcantly higher in the epilepsy group than in the PBS
group (P o 0.01). Pretreatment with either EPO or CEPO further
enhanced the expression of bcl-xl protein in epileptic rats, and the
expression intensity of bcl-xl protein increased with time, peaking
at 24 hours. The expression intensity of bcl-xl protein at 24 hoursroups.
oietin Carbamylated erythropoietin Ethanol AG490
1828) 8017 (1257) 7724 (1628) 8326 (1833)
2351) 13,932 (2621) 13,925 (2947)* 14,738 (2539)
2515) 17,571 (2947) 18,864 (3073)* 20,029 (4066)
3953) 25,017 (4243) 28,770 (5434)* 32,942 (5442)
5686)†,‡ 32,627 (5144)†,‡ 43,923 (6459)* 53,640 (6427)§
50 µm
50 µm
50 µm 50 µm
50 µm
50 µm
Figure 5. Recombinant human erythropoietin (rhEPO) and carbamylated erythropoietin (CEPO) upregulate expression of bcl-xl protein in the myocardium of rats with kainic
acid-induced epilepsy. Myocardial bcl-xl protein expression was determined by immunohistochemistry at 0, 2, 6, 12, and 24 hours after the onset of seizures. Representative
images (400 ; 24 hours after onset of seizures) of bcl-xl expression in the myocardium of (A) control and (B) epileptic rats and epileptic rats treated with (C) ethanol,
(D) rhEPO, (E) CEPO, or (F) AG490. The cytoplasm of positive cells is stained brown (shown by arrows).
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epilepsy group (both P values o 0.01). AG490 treatment reduced
the expression of bcl-xl protein in epileptic rats, and the expres-
sion intensity of bcl-xl protein decreased with time, reaching
lowest levels at 24 hours. The expression intensity of bcl-xl protein
at 24 hours was signiﬁcantly lower in the AG490 group than in the
ethanol group (P o 0.01). Additionally, the expression intensity of
bcl-xl protein at 2, 6, 12, and 24 hours was signiﬁcantly lower in
the AG490 group than in the EPO and CEPO groups (all P values
o 0.01).EPO upregulates the expression of JAK2 mRNA
In situ hybridization was performed to examine whether JAK2
mRNA expression in the myocardium is altered in the experimental
model of epilepsy and whether EPO and CEPO treatment could
reverse such alterations. As shown in Figure 6A, JAK2 mRNA was
expressed at low levels in the myocardium of normal rats, and no
signiﬁcant differences were detected in expression levels between
the normal control and PBS-treated groups (P 4 0.05). In the
epilepsy group, expression of JAK2 mRNA in the myocardium
increased as early as 2 hours after the onset of seizures and
reached an observed maximum at 24 hours (P o 0.01 compared
with the PBS group). AG490 treatment reduced the expression of
JAK2 mRNA in epileptic rats with expression intensity decreasing
with time and reaching lowest levels after 24 hours (P o 0.01compared with the ethanol-treated control group). Pretreatment
with EPO enhanced the expression of JAK2 mRNA in epileptic
rats, and the expression intensity of JAK2 mRNA increased with
time, reaching an observed maximum at 24 hours. The expres-
sion intensity of JAK2 mRNA at 24 hours was signiﬁcantly higher
in the EPO group than in the epilepsy group (P o 0.01). In
contrast, pretreatment with CEPO showed no signiﬁcant inﬂu-
ence on the expression of JAK2 mRNA in epileptic rats. No
signiﬁcant difference was noted in the expression intensity of
JAK2 mRNA at 24 hours between the CEPO group and epilepsy
group (P 4 0.05).EPO upregulates the expression of STAT5a mRNA
The expression of STAT5 mRNA in the myocardium of epileptic
rats was similarly detected by in situ hybridization. STAT5a mRNA
was expressed at low levels in the myocardium of normal rats
(Figure 6B) and no signiﬁcant difference was detected between
the normal control and PBS groups (P 4 0.05). In the epilepsy
group, the expression of STAT5a mRNA in the myocardium was
signiﬁcantly (P o 0.05) increased 2 hours after the onset of
seizures and continued to increase during the 24-hour observation
period relative to the PBS group. AG490 treatment reduced the
expression of STAT5a mRNA in epileptic rats, with expression
intensity decreasing with time and reaching its lowest level at 24
hours (P o 0.01 compared with the ethanol group). Pretreatment
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Figure 6. Recombinant human erythropoietin (rhEPO), in contrast to carbamylated
erythropoietin (CEPO), signiﬁcantly upregulates expression of Janus kinase
2 mRNAs in the myocardium of rats with kainic acid-induced epilepsy. Myocardial
expression of Janus kinase 2 mRNA for control (ie, phosphate buffered saline) and
epileptic rats and epileptic rats treated with rhEPO, CEPO, ethanol, or AG490 was
determined by in situ hybridization at 0, 2, 6, 12, and 24 hours after the onset of
seizures. The integrated optical density of mRNA staining was measured using
Image-Pro Plus 6.0 software (Media Cybernetics, USA). Data shown are expressed
as mean (SD) (n ¼ 6). (A) P o 0.01 versus the phosphate buffered saline group, (B)
P o 0.01 versus the epilepsy group, (C), P o 0.05 versus the epilepsy group, and
(D) P o 0.01 versus the AG490 group.
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with the expression intensity increasing with time and reaching
highest observed levels at 24 hours. The expression intensity of
STAT5a mRNA at 24 hours was signiﬁcantly higher in the EPO
group than in the epilepsy group (P o 0.01). In contrast, pretreat-
ment with CEPO showed no signiﬁcant inﬂuence on the expression
of STAT5a mRNA in epileptic rats. Thus, no signiﬁcant difference
was noted in the expression intensity of STAT5a mRNA at 24 hours
between the CEPO-treated and epilepsy groups (P 4 0.05).
STAT5b mRNA was also lowly expressed in the myocardium of
normal rats. No signiﬁcant difference was noted in the expression
intensity of STAT5b mRNA between the normal control group and
PBS group (P 4 0.05). In the epilepsy group, the expression of0.48
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Figure 7. The levels of p-Janus kinase 2 (JAK2), p-STAT5a, and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) in the myocardium of control (ie, phosphate
buffered saline [PBS]) and epileptic rats as well as epileptic rats treated with
recombinant human erythropoietin (EPO), carbamylated EPO (CEPO), ethanol, or
AG490 were determined by Western blot 24 hours after the onset of seizures.
Recombinant human EPO, in contrast to CEPO, signiﬁcantly upregulates the levels
of p-JAK2 and p-STAT5a in the myocardium of rats with kainic acid-induced
epilepsy.STAT5b mRNA in the myocardiumwas slightly upregulated 2 hours
after seizure onset. However, there was no signiﬁcant difference in
the expression intensity of STAT5b mRNA between the epilepsy
group and PBS group (P 4 0.05). Pretreatment with either EPO or
CEPO had no signiﬁcant inﬂuence on the expression of STAT5b
mRNA in epileptic rats.
EPO promotes the activation of JAK2 and STAT5 proteins
Western blotting was performed to examine whether the levels
of p-JAK2 and p-STAT5 proteins in the myocardiumwere altered in
epilepsy, and if EPO and CEPO treatment inﬂuences such changes.
As shown in Figure 7, p-JAK2 levels were upregulated in the
epilepsy and ethanol groups. AG490 treatment reduced the level of
p-JAK2, whereas pretreatment with EPO enhanced the level of
p-JAK2. In contrast, pretreatment with CEPO had no signiﬁcant
inﬂuence on the level of p-JAK2 in rats with KA-induced epilepsy.
Similar results were also obtained for p-STAT5 levels (Figure 7).Discussion
Apoptosis has been implicated in many heart disorders.18,19,20
Although it is clear that myocardial injury can occur in patients
with intractable epilepsy,5,6,17,21,22 it has not previously been
known whether myocardial cell apoptosis is a contributing factor.
Importantly, our novel data reveal that myocardial cell apoptosis
increases after induction of experimental epilepsy and suggest that
this pathway may indeed be involved in epilepsy-related myocar-
dial damage. At a mechanistic level, we demonstrated that the
induction of epilepsy upregulates the expression of caspase-3
protein, a critical regulator of apoptosis, providing further evi-
dence to support myocardial cell apoptosis occurring in epilepsy.
Although bcl-xl, an antiapoptotic bcl-2 family protein, is also
upregulated in parallel with caspase-3, we speculate that this is
a self-defense mechanism of the body that occurs in response to
apoptosis. Therefore, these ﬁndings suggest that myocardial cell
apoptosis may contribute to myocardial injury in epilepsy and be
of clinical signiﬁcance.
EPO can protect multiple organs, such as the heart and brain,
against various types of injuries.11,23,24 Multiple lines of evidence
demonstrate that EPO exerts protective effects dependent on its
antiapoptotic action via upregulation of antiapoptotic genes and
downregulation of apoptotic genes.10,25 In the present study, we
demonstrated that EPO pretreatment signiﬁcantly reduced the rate
of apoptosis in myocardial cells, upregulated bcl-xl expression, and
downregulated caspase-3 expression, suggesting that EPO is able to
prevent myocardial injury in epilepsy by antagonizing apoptosis.
Previous studies have shown that activation of the JAK/STAT
pathway inhibits apoptosis of myocardial cells and contributes to
cardioprotection.16,26 AG490 is a selective inhibitor of JAK2 that
can effectively block tyrosine phosphorylation of JAK2 and STAT
activation.27 Our results showed that AG490 treatment increased
the percentage of apoptotic myocardial cells, upregulated the
expression of caspase-3 protein, and downregulated the expres-
sion of bcl-xl in epileptic rats. This suggests that activation of the
JAK2-STAT5 pathway can exert cardioprotection in epilepsy by
inhibiting myocardial cell apoptosis. Further, this ﬁnding is con-
sistent with the previous observation that STAT5 can regulate the
transcription of genes that encode bcl-2 family members and
caspases.28
EPO-mediated cardioprotection from injury has been attributed
to activation of the JAK/STAT pathway and downstream antiapop-
totic events.12,15,16 Our results demonstrated that EPO treatment
could activate the JAK2/STAT5a pathway and thereby inhibit
myocardial cell apoptosis by upregulating the expression of
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epileptic rats. In contrast, EPO pretreatment induced no obvious
changes in the expression levels of STAT5b mRNA. Interestingly,
although the induction of epilepsy also increased the expression of
JAK2 and STAT5a mRNAs in the myocardium, the degree of
upregulation of JAK2 and STAT5a mRNAs in response to epilepsy
alone was weaker than when it was combined with EPO pretreat-
ment. More importantly, the number of apoptotic myocardial cells
was elevated in rats with epilepsy but was reduced in those rats
pretreated with EPO. Therefore, it appears that epilepsy-induced
activation of the JAK2/STAT5a pathway, similar to bcl-xl upregu-
lation, represents a self-defense mechanism in response to myo-
cardial injury. Thus, these data suggest that EPO pretreatment can
protect myocardial cells from apoptosis via the JAK2/STAT5 path-
way in rats with KA-evoked epilepsy.
Despite potent protective effects in various tissues, EPO may
cause unwanted secondary effects. For example, long-term use of
high-dose EPO can lead to erythrocytosis and subsequent cardio-
vascular dysfunction.29–31 CEPO may be an ideal alternative to EPO
because the former does not stimulate erythropoiesis but can still
provide tissue protection.32 It has been demonstrated that CEPO
protects the myocardium from ischemia-reperfusion injury but
does not raise the hemoglobin concentration.33 Instead of binding
to the classical EPO receptor, CEPO signaling requires formation of
a heterodimer consisting of the EPO receptor and the β common
receptor. Therefore, CEPO exerts tissue protection perhaps via a
mechanism that differs from that of EPO.33 In the present study,
we demonstrated that CEPO showed a similar antiapoptotic effect
to EPO in the myocardium of epileptic rats. However, CEPO
pretreatment had no signiﬁcant inﬂuence on the expression of
JAK2 and STAT5 mRNAs and proteins, suggesting that its anti-
apoptotic action in the myocardium of rats with KA-induced
epilepsy occurs via a pathway independent of JAK2/STAT5 signal-
ing. This result is consistent with a previous observation that CEPO
does not activate the JAK2/STAT5 pathway in vitro.32 Based on
previous data, we speculate that CEPO exerts cardioprotection
against myocardial injury in epilepsy, possibly by inhibiting
myocardial apoptosis via a phosphatidylinositol 3-kinase (PI3K)/
protein kinase B (Akt)-dependent mechanism.25
This epileptic model has been successfully established by KA
microinjected into nucleus amygdalae in rats, this model is appli-
cable for temporal lobe epilepsy. However, cost and a complicated
operation may be limiting factors for the use of the model. The use
of KA and stereotaxic apparatus may be associated with higher
treatment costs. On the other hand, pathologic physiology change
of this model is not consistent with epilepsy induced by speciﬁc
factors, including trauma and stroke. In that respect, this model
never appears to represent a sensitive and relevant approach.Conclusions
The data from this study provide the ﬁrst evidence that
myocardial cell apoptosis may contribute to myocardial injury in
epilepsy. Furthermore, EPO protects myocardial cells from apop-
tosis via the JAK2/STAT5 pathway in rats with KA-evoked epilepsy.
In contrast, CEPO exerts antiapoptotic action in the myocardium of
rats with KA-induced epilepsy perhaps via a pathway independent
of JAK2 and STAT5. CEPO may therefore represent a rational and
effective therapeutic alternative for myocardial injury in epilepsy.Acknowledgments
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